Literature DB >> 11454810

Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.

J Vlachogiannakos1, A K Tang, D Patch, A K Burroughs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11454810      PMCID： PMC1728379          DOI： 10.1136/gut.49.2.303

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  48 in total

1.  Angiotensin II induces contraction and proliferation of human hepatic stellate cells.

Authors:  R Bataller; P Ginès; J M Nicolás; M N Görbig; E Garcia-Ramallo; X Gasull; J Bosch; V Arroyo; J Rodés
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man.

Authors:  J H LARAGH; M ANGERS; W G KELLY; S LIEBERMAN
Journal:  JAMA       Date:  1960-09-17       Impact factor: 56.272

3.  Control of glomerular filtration rate by renin-angiotensin system.

Authors:  J E Hall; A C Guyton; T E Jackson; T G Coleman; T E Lohmeier; N C Trippodo
Journal:  Am J Physiol       Date:  1977-11

4.  A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report.

Authors:  D Lebrec; T Poynard; J Bernuau; E Bercoff; O Nouel; J P Capron; R Poupon; M Bouvry; B Rueff; J P Benhamou
Journal:  Hepatology       Date:  1984 May-Jun       Impact factor: 17.425

Review 5.  Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis.

Authors:  J Vlachogiannakos; J Goulis; D Patch; A K Burroughs
Journal:  Aliment Pharmacol Ther       Date:  2000-07       Impact factor: 8.171

6.  Renin, aldosterone and renal haemodynamics in cirrhosis with ascites.

Authors:  V Arroyo; J Bosch; M Mauri; J Viver; A Mas; F Rivera; J Rodes
Journal:  Eur J Clin Invest       Date:  1979-02       Impact factor: 4.686

7.  Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels.

Authors:  C I Johnston; B H Clappison; W P Anderson; M Yasujima
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

8.  Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis.

Authors:  L S Eriksson; B Kågedal; J Wahren
Journal:  Am J Med       Date:  1984-05-31       Impact factor: 4.965

9.  Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril.

Authors:  S A Atlas; D B Case; Z Y Yu; J H Laragh
Journal:  Am J Med       Date:  1984-08-20       Impact factor: 4.965

10.  Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites.

Authors:  V Arroyo; J Bosch; M Mauri; F Ribera; F Navarro-López; J Rodés
Journal:  Eur J Clin Invest       Date:  1981-06       Impact factor: 4.686
View more
  7 in total

Review 1.  Management of portal hypertension.

Authors:  D N Samonakis; C K Triantos; U Thalheimer; D W Patch; A K Burroughs
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

Review 2.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

Review 3.  Nonalcoholic fatty liver disease as a component of the metabolic syndrome.

Authors:  Mouen A Khashab; Suthat Liangpunsakul; Naga Chalasani
Journal:  Curr Gastroenterol Rep       Date:  2008-02

4.  Quantitative modeling of the physiology of ascites in portal hypertension.

Authors:  David G Levitt; Michael D Levitt
Journal:  BMC Gastroenterol       Date:  2012-03-27       Impact factor: 3.067

Review 5.  Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.

Authors:  Wah-Kheong Chan; Soek-Siam Tan; Siew-Pheng Chan; Yeong-Yeh Lee; Hoi-Poh Tee; Sanjiv Mahadeva; Khean-Lee Goh; Anis Safura Ramli; Feisul Mustapha; Nik Ritza Kosai; Raja Affendi Raja Ali
Journal:  J Gastroenterol Hepatol       Date:  2022-02-08       Impact factor: 4.369

6.  Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection.

Authors:  Lindsey J Reese; Diane S Tider; Alicia C Stivala; Dawn A Fishbein
Journal:  AIDS Res Treat       Date:  2012-11-01

Review 7.  Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.

Authors:  John S Lubel; Chandana B Herath; Louise M Burrell; Peter W Angus
Journal:  J Gastroenterol Hepatol       Date:  2008-06-28       Impact factor: 4.029
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.